News | January 25, 2025
Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
Q3 FY25 revenue up 24% to Rs 3,230 crore
Q3 FY25 revenue up 24% to Rs 3,230 crore
Acquisition expands high-value medical platform
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Subscribe To Our Newsletter & Stay Updated
